NDA for Alzheimer’s Combined Drug Namzaric Approved by FDA

NDA for Alzheimer’s Combined Drug Namzaric Approved by FDA
shutterstock_170915609Actavis and Adamas Pharmaceuticals Inc. announced that the US Food and Drug Administration has accepted Namzaric's New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric, is also known as MDX-8704. In cases of known difficulty in swallowing, the drug may be sprinkled and mixed in the patient's food. "Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy.  Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer's disease. Additionally, data has shown that combination therapy with Namenda XR and an AChEI demonstrated greater improvement in cognition and global function verses an AChEI alone. Along with our partner Adamas, we are proud that this important t
Subscribe or to access all post and page content.

One comment

  1. Mrs James Harriss says:

    We are living on social security and can not afford the cost of the Namazaric. The doctor gave us a sample box , which we started July 21st. My husband is 90years old , and needs help. We would be thankful for help.

Leave a Comment

Your email address will not be published. Required fields are marked *